In February 2009, I urged several Motley Fool colleagues to add Mead Johnson Nutrition
Mead Johnson Nutrition is one of the leading companies of products for infant and children's nutrition. It was spun out of Bristol-Myers Squibb
Pfizer could follow the same script
That success can't have gone unnoticed at rival pharma Pfizer
One of those businesses is nutrition, inherited from the acquisition of Wyeth, which competes directly with Mead Johnson. With 2010 revenues of $1.9 billion to Mead's $3.1 billion, Pfizer's nutrition unit is smaller, but it shares the same attractive qualities, including brand power and a strong position in some of the world's growth markets (China, the Philippines, and Mexico are among its top markets).
Be ready when opportunity knocks at your door
At present, Mead Johnson provides an aggressive valuation benchmark for Pfizer nutrition, but any time a business of this caliber comes to market, it's a situation worth following. In order to do that, I recommend you add Pfizer to your watchlist in order to get our coverage of any major development affecting the company, including the spin-off of any of the firm's divisions.
Click on Mead Johnson, Pfizer, and Bristol-Myers Squibb to add them to your watchlist, or start a new watchlist and add any company you want. You'll get valuable updates as well as immediate access to a new special report, "6 Stocks to Watch from David and Tom Gardner."